⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2139644 | 0.76 | CDK2 (0.51) | — | |
| SCHEMBL19915568 | 0.74 | CDK2 (0.46) | — | |
| SCHEMBL3316049 | 0.73 | — | — | |
| SCHEMBL786399 | 0.73 | CDK2 (0.44) | — | |
| SCHEMBL2628925 | 0.73 | — | — | |
| SCHEMBL21375682 | 0.73 | CDK2 (0.44) | — | |
| SCHEMBL682219 | 0.71 | — | — | |
| SCHEMBL13748159 | 0.71 | — | — | |
| SCHEMBL22282340 | 0.71 | — | — | |
| SCHEMBL20273004 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044757-A1 | AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044778-A2 | NOVEL MODULATORS OF FSHR AND USES THEREOF | CELMATIX INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20200069796-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor | ACERTA PHARMA BV (NL) | 2020-03-05 | — | — | US | disclosed |
| US-9981999-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170362260-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-21 | — | — | US | disclosed |
| US-9683002-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9630945-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2017-04-25 | — | — | US | disclosed |
| US-9630945-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2017-04-25 | — | — | US | disclosed |
| US-20170037030-A1 | AUTOTAXIN INHIBITORS | NOVARTIS AG (CH) | 2017-02-09 | — | — | US | disclosed |
| US-20170007614-A1 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2017-01-12 | — | — | US | disclosed |
| US-9409895-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2016-08-09 | — | — | US | disclosed |
| US-20150307475-A1 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2015-10-29 | — | — | US | disclosed |
| US-20140171404-A1 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-20140171403-A1 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| WO-2012082857-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | WO | disclosed |